Trichotillomania: Case report of pharmacological treatment outcome with clomipramine

Mariusso, Laís Medina; Costa, Amália Christina Brito; Canassa, Thaisa Carla; Tanouye, Andressa Tiemi de Andrade; Porcu, Mauro

doi:10.1016/j.psychres.2019.112663

Cited by 2 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Sani et al have pointed out that the average dosage used in the Ninan et al trial (116.7 mg/day) was lower than that which is normally used to treat OCD, but there have been case reports of successful clomipramine monotherapy at 125 mg/day and dual therapy at 50 mg/day with behavioral therapy. 21,32,33 T A B L E 2 Traditional pharmacotherapy for TTM 2,5,[19][20][21]23,25,[31][32][33][34][35][36][37][38][39][40][41] Drug name…”

Section: Tricyclic Antidepressantsmentioning

confidence: 99%

“…Clomipramine was found to decrease symptoms of TTM more than placebo, but not significantly so 31 . Sani et al have pointed out that the average dosage used in the Ninan et al trial (116.7 mg/day) was lower than that which is normally used to treat OCD, but there have been case reports of successful clomipramine monotherapy at 125 mg/day and dual therapy at 50 mg/day with behavioral therapy 21,32,33 …”

Section: Treatment Of Ttmmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in the treatment of trichotillomania (hair‐pulling disorder)

Everett

Jafferany

Skurya

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Trichotillomania (TTM) is a condition in which affected individuals pull out their hair resulting in hair loss. This disorder affects roughly 0.5% to 2.0% of the population and can have significant psychological morbidity. Behavioral therapy has been used with success in the treatment of TTM, but not all patients are willing or able to comply with this treatment strategy. There is a need for effective pharmacological treatment options. Historically, pharmacotherapy for TTM has been inadequate in most cases, but recent advances have been made in this regard. Fluoxetine, clomipramine, olanzapine, and naltrexone have all been used in the treatment of TTM, but evidence of benefit has varied, and side effect profiles can limit practical utility. Recent advances in the understanding of the pathophysiology of TTM, as well as evidence of benefit seen with some glutamate-modulating agents such as N-acetylcysteine and dronabinol, have provided newer potential pharmacotherapy options.

show abstract